Hi Felix,
Descartes has been a stellar growth stock for years. Over the past five years, its share price has gained 175% and it is in positive territory once gain this year (+31%). Since the company is a logisicts and supply chain management company, the demand for, and the importance of its products where quite evident during the pandemic. Economic lockdowns has been a nightmare for companies as they try and navigate a very complicated global supply chain.
The pandemic however, only likely accelerated adoption of their products. The need will remains whether there is a vaccine or not. In terms of actual supply chain logistics for the vaccine - I am unclear if they will benefit directly. They could benefit in two segments: Manufacturing & distribution and Transportation & Logistics. Notably, they've highlighted their capacity in the Pharmaceutical Cold Chain Logistics recently.
I do not see any of the major vaccine players listed as customers, but that is not to say they don't use other companies that DSG deals with directly . Furthermore, I have yet to see any announcements in terms of government support in this area. Once again, not to say they won't be involved but nothing explicitly stated anywhere.
Mat